170 related articles for article (PubMed ID: 8203840)
1. Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase.
Rathod PK; Reshmi S
Antimicrob Agents Chemother; 1994 Mar; 38(3):476-80. PubMed ID: 8203840
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum.
Jiang L; Lee PC; White J; Rathod PK
Antimicrob Agents Chemother; 2000 Apr; 44(4):1047-50. PubMed ID: 10722510
[TBL] [Abstract][Full Text] [Related]
3. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
4. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor.
Yin MB; Guimaraes MA; Zhang ZG; Arredondo MA; Rustum YM
Cancer Res; 1992 Nov; 52(21):5900-5. PubMed ID: 1394217
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of Plasmodium falciparum thymidylate synthase: interactions with high-affinity metabolites of 5-fluoroorotate and D1694.
Hekmat-Nejad M; Rathod PK
Antimicrob Agents Chemother; 1996 Jul; 40(7):1628-32. PubMed ID: 8807052
[TBL] [Abstract][Full Text] [Related]
6. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme.
Keyomarsi K; Samet J; Molnar G; Pardee AB
J Biol Chem; 1993 Jul; 268(20):15142-9. PubMed ID: 8325888
[TBL] [Abstract][Full Text] [Related]
7. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.
Ward WH; Kimbell R; Jackman AL
Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289
[TBL] [Abstract][Full Text] [Related]
8. ICI D1694 and idoxuridine: a synergistic antitumor combination.
Pressacco J; Hedley DW; Erlichman C
Cancer Res; 1994 Jul; 54(14):3772-8. PubMed ID: 8033097
[TBL] [Abstract][Full Text] [Related]
9. Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.
Pressacco J; Erlichman C
Biochem Pharmacol; 1993 Dec; 46(11):1989-97. PubMed ID: 8267649
[TBL] [Abstract][Full Text] [Related]
10. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.
Gibson W; Bisset GM; Marsham PR; Kelland LR; Judson IR; Jackman AL
Biochem Pharmacol; 1993 Feb; 45(4):863-9. PubMed ID: 7680860
[TBL] [Abstract][Full Text] [Related]
11. Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1694, thymidylate synthase inhibitor, using single cell assays.
Schöber C; Gibbs JF; Yin MB; Slocum HK; Rustum YM
Biochem Pharmacol; 1994 Aug; 48(5):997-1002. PubMed ID: 8093112
[TBL] [Abstract][Full Text] [Related]
12. Modulation of target enzyme associated with the action of antifolates.
Rustum YM; Cao S; Yin MB
Adv Enzyme Regul; 1994; 34():57-70. PubMed ID: 7942285
[TBL] [Abstract][Full Text] [Related]
13. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.
Pressacco J; Mitrovski B; Erlichman C; Hedley DW
Cancer Res; 1995 Apr; 55(7):1505-8. PubMed ID: 7882359
[TBL] [Abstract][Full Text] [Related]
14. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694.
Jackman AL; Gibson W; Brown M; Kimbell R; Boyle FT
Adv Exp Med Biol; 1993; 339():265-76. PubMed ID: 7513935
[TBL] [Abstract][Full Text] [Related]
15. ICI D1694, an inhibitor of thymidylate synthase for clinical study.
Jackman AL; Jodrell DI; Gibson W; Stephens TC
Adv Exp Med Biol; 1991; 309A():19-23. PubMed ID: 1789205
[TBL] [Abstract][Full Text] [Related]
16. Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling.
Aroonsri A; Akinola O; Posayapisit N; Songsungthong W; Uthaipibull C; Kamchonwongpaisan S; Gbotosho GO; Yuthavong Y; Shaw PJ
Int J Parasitol; 2016 Jul; 46(8):527-35. PubMed ID: 27150044
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats.
Jodrell DI; Newell DR; Gibson W; Hughes LR; Calvert AH
Cancer Chemother Pharmacol; 1991; 28(5):331-8. PubMed ID: 1914075
[TBL] [Abstract][Full Text] [Related]
18. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors.
Yuthavong Y; Yuvaniyama J; Chitnumsub P; Vanichtanankul J; Chusacultanachai S; Tarnchompoo B; Vilaivan T; Kamchonwongpaisan S
Parasitology; 2005 Mar; 130(Pt 3):249-59. PubMed ID: 15796007
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Curtin NJ; Harris AL
Biochem Pharmacol; 1988 Jun; 37(11):2113-20. PubMed ID: 3377815
[TBL] [Abstract][Full Text] [Related]
20. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
